Istradefylline, a selective A2AR antagonist, has been approved for Parkinson’s disease (PD) adjunctive therapy and showed neuroprotective effects in PD and Alzheimer’s disease. The gene discussed is ADORA2A; the disease is early-onset autosomal dominant Alzheimer disease.